Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

Key growth drivers include increased healthcare spending, the rise of chronic diseases, and advancements in nanotechnology.

The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...

DelveInsight's "INBRIJA Market Size, Forecast, and Market Insight Report" highlights the details around INBRIJA, which consists of a dry powder formulation of levodopa for oral inhalation with the ...

Several companies are advancing treatments for anal cancer, including Merck (KEYTRUDA), BioMimetix (BMX-001), Novartis (KFA115), and Bicara Therapeutics (BCA101), among others. As immunotherapy ...

Growth is driven by the aging population, rising chronic diseases, and self-administration practices. Advances in technology, new product launches, and favorable policies bolster growth. Injectable ...

(Reuters) -Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment ...

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

Novartis AG blocked MSN Laboratories Pvt. Ltd.’s attempt to launch a copy of its blockbuster Entresto before July 16, as a ...

The global Healthcare Contract Manufacturing Market size is projected to be valued at USD 183.7 billion in 2023 and reach USD 347.5 billion by 2030, growing at a CAGR of 9.5% according to a new report ...